OncoMatch/Clinical Trials/NCT06081920
A Study of IBI363 in Subjects With Advanced Melanoma
Is NCT06081920 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies IBI363 for melanoma.
Treatment: IBI363 — This is an open-lable, multicenter Phase II study to evaluate the safety, tolerability, and efficacy of IBI363 in advanced melanoma patients
Check if I qualifyExtracted eligibility criteria
Cancer type
Melanoma
Disease stage
Required: Stage III, IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systemic standard treatment — first-line
Progression or recurrence after at least first-line systemic standard treatment
Lab requirements
Blood counts
hemoglobin <90 g/L; ANC <1.5 × 10^9/L; Platelet count <100 × 10^9/L
Kidney function
Serum creatinine >1.5 × ULN or CCr <45 mL/min (Cockcroft Fault formula, actual body weight)
Liver function
Total bilirubin >1.5 × ULN; AST or ALT >3 × ULN; If tumor liver metastasis, AST or ALT >5.0 × ULN
At baseline (within 7 days before the first administration of the study drug), there were any hematological abnormalities as follows: hemoglobin<90 g/L; Absolute neutrophil count (ANC)<1.5 × 10^9/L; Platelet count<100 × 10^9/L. At baseline (within 7 days prior to first administration), there were any serum biochemical abnormalities as follows: Total bilirubin>1.5 × ULN; AST or ALT>3 × ULN; If it is tumor liver metastasis, AST or ALT>5.0 × ULN; Serum creatinine>1.5 × ULN or CCr<45 mL/min, using the Cockcroft Fault formula to calculate CCr (using actual body weight); Albumin<30 g/L.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify